July 26, 2022Press Release
Mass Eye and Ear Remains Top Hospital in New England for Eye and Ear, Nose and Throat Care
Ryan Jaslow | Director of External Communications for Specialty Hospitals at Mass General Brigham
617-573-4385 | email@example.com
U.S. News & World Report 2022-2023 “Best Hospitals” survey ranks Mass Eye and Ear no. 4 in nation for Ophthalmology and no. 4 in the U.S. for Otolaryngology. Both departments remain no. 1 in New England.
Boston, Mass. — Mass Eye and Ear and Massachusetts General Hospital, members of Mass General Brigham, have been recognized by U.S. News & World Reportin the 2022-2023 “Best Hospitals” rankings with the no. 4 ranking for ophthalmology (eye care) and no. 4 ranking in otolaryngology (ear, nose and throat care). The departments, shared across both hospitals, are no. 1 in New England for the 32nd year in a row, since the rankings were first established in 1990.
The Mass Eye and Ear/Mass General Department of Ophthalmology earned the no. 4 national ranking for 2022-2023. This ranking is based entirely on a reputational survey of board-certified ophthalmologists around the country. Realizing the need for more objective and transparent reporting in the field, the Department has published a Quality and Outcomes Report since 2010.
The Mass Eye and Ear/Mass General Department of Otolaryngology–Head and Neck Surgery earned the no. 4 ranking for U.S. programs for 2022-2023. The otolaryngology ranking is based on scoring criteria including quality of care, patient safety and national reputation as surveyed by board-certified otolaryngologists.
In 2009, Mass Eye and Ear and Mass General announced that Mass Eye and Ear physicians would lead and staff the Departments of Ophthalmology and Otolaryngology–Head and Neck Surgery at Mass General, which is why both hospitals are named in the ranking.
“We are incredibly honored and humbled to once again be named the best hospital for eye and ENT specialty care in New England, and to again be ranked among the top departments of their kind in the nation,” said John Fernandez, president of Mass Eye and Ear. “These rankings are a reflection of the dedication and tireless commitment of our faculty and staff, who strive to provide top care for any patient who comes through our doors and to advance research for diseases related to vision, hearing and head and neck cancer.”
Several other Mass General Brigham hospitals were also honored by U.S. News & World Report. Massachusetts General Hospital and Brigham and Women’s Hospital once again earned spots on the Honor Roll among the top hospitals in the country. Brigham and Women’s Hospital is #1 in women’s health, ranked #1 for obstetrics and gynecology in the nation.
Two other Mass General Brigham specialty hospitals – McLean Hospital and Spaulding Rehabilitation – were recognized for national excellence. McLean Hospital was ranked #1 in the nation for psychiatry. Spaulding Rehabilitation is #1 in rehabilitation in New England and ranked #3 in rehabilitation in the nation.
Mass General Brigham is honored to have five nationally ranked hospitals.
About Mass Eye and Ear
Massachusetts Eye and Ear, founded in 1824, is an international center for treatment and research and a teaching hospital of Harvard Medical School. A member of Mass General Brigham, Mass Eye and Ear specializes in ophthalmology (eye care) and otolaryngology–head and neck surgery (ear, nose and throat care). Mass Eye and Ear clinicians provide care ranging from the routine to the very complex. Also home to the world's largest community of hearing and vision researchers, Mass Eye and Ear scientists are driven by a mission to discover the basic biology underlying conditions affecting the eyes, ears, nose, throat, head and neck and to develop new treatments and cures. In the 2022–2023 “Best Hospitals” survey, U.S. News & World Report ranked Mass Eye and Ear #4 in the nation for eye care and #4 for ear, nose and throat care. For more information about life-changing care and research at Mass Eye and Ear, visit our blog,Focus, and follow us on Instagram,TwitterandFacebook.